AbbVie Inc.

ABBVSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1551152

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$54.3B	$58.1B	$56.2B	$45.8B	$33.3B
Cost of Goods and Services Sold	$20.4B	$17.4B	$17.4B	$15.4B	$7.4B
Gross Profit	$12.1B	$10.7B	$8.6B	$11.0B	$10.6B
Selling, General and Administrative Expense	$12.9B	$15.3B	$12.3B	$11.3B	$6.9B
Operating Income (Loss)	$12.8B	$18.1B	$17.9B	$11.4B	$13.0B
Interest Expense	$2.2B	$2.2B	$2.4B	$2.5B	$1.8B
Other Nonoperating Income (Expense)	-$4.7B	-$2.4B	-$2.5B	-$5.6B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$135.2B	$134.7B	$138.8B	$146.5B	$150.6B
Assets, Current	$25.6B	$33.0B	$28.5B	$27.9B	$24.2B
Cash and Cash Equivalents, at Carrying Value	$5.5B	$12.8B	$9.2B	$9.7B	$8.4B
Accounts Receivable, after Allowance for Credit Loss, Current	$10.9B	$11.2B	$11.3B	$10.0B	$8.8B
Inventory, Net	$4.2B	$4.1B	$3.6B	$3.1B	$3.3B
Liabilities, Current	$38.7B	$37.8B	$29.5B	$35.2B	$28.7B
Long-term Debt	$64.5B	$66.8B	$59.2B	$63.1B

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	$22.8B	$24.9B	$22.8B	$17.6B	$13.3B
Net Cash Provided by (Used in) Investing Activities	-$2.0B	-$623.0M	-$2.3B	-$37.6B	$596.0M
Net Cash Provided by (Used in) Financing Activities	-$17.2B	-$24.8B	-$19.0B	-$11.5B	$18.7B
Payments to Acquire Property, Plant, and Equipment	$777.0M	$695.0M	$787.0M	$798.0M	$552.0M
Payments of Dividends	$10.5B	$10.0B	$9.3B	$7.7B	$6.4B
Payments for Repurchase of Common Stock	$2.0B	$1.5B	$934.0M	$978.0M	$629.0M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)